Citation: Qingqing Xiao, Xiaotong Li, Chang Liu, Yi Yang, Yuqi Hou, Ying Wang, Mengxiang Su, Wei He. Liposome-based anchoring and core-encapsulation for combinatorial cancer therapy[J]. Chinese Chemical Letters, ;2022, 33(9): 4191-4196. doi: 10.1016/j.cclet.2022.01.083 shu

Liposome-based anchoring and core-encapsulation for combinatorial cancer therapy

School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China

sumengxiang@cpu.edu.cn

weihe@cpu.edu.cn

Received Date: 15 November 2021
Revised Date: 20 January 2022
Accepted Date: 27 January 2022
Available Online: 3 February 2022

Figures(5)

Downregulated pro-apoptotic protein in cancer cells compromises the chemotherapy by a cytotoxic drug. Here, we report co-delivery of a pro-apoptotic protein, caspase 3 (Cas 3), and cytotoxic agent, oridonin (ORD), for synergistic cancer treatment, using a method of liposome-based anchoring and core encapsulation. First, ORD is modified with hyaluronic acid (HA) to improve its solubility. Then, the targeted co-delivery system is prepared by assembling the conjugate HA-ORD onto the Cas 3-loaded liposomes, which the surface HA can target the CD44 receptor on cancer cells. In vitro, the co-loaded liposomes (120 nm) are specifically taken up by 4T1 cells and endow a 1.5-fold increase of Cas 3. After intravenous injection into the tumor-bearing mice, the liposomes accumulate in the tumor with high efficacy and significantly inhibit tumor growth via promoting apoptosis and anti-proliferation of cancer cells. Mechanistically, the co-delivery works synergistically by upregulating the activated Cas form, cleaved-Cas 3.
- Liposomes,
- Co-delivery,
- Chemotherapy,
- Pro-apoptotic protein,
- Tumor targeting
1. [1]
  J. Ferlay, M. Colombet, I. Soerjomataram, et al., Int. J. Cancer 149 (2021) 778-789. doi: 10.1002/ijc.33588
2. [2]
  M.O. Hengartner, Nature 407 (2000) 770-776. doi: 10.1038/35037710
3. [3]
  Y. Zhao, N.R. Foster, J.P. Meyers, et al., J. Thorac. Oncol. 10 (2015) 172-180. doi: 10.1097/JTO.0000000000000383
4. [4]
  A.G. Porter, R.U. Jänicke, Cell Death Differ. 6 (1999) 99-104. doi: 10.1038/sj.cdd.4400476
5. [5]
  P. Yadav, R. Yadav, S. Jain, A. Vaidya, Chem. Biol. Drug Des. 98 (2021) 144-165. doi: 10.1111/cbdd.13860
6. [6]
  J. Hu, X. Yuan, F. Wang, et al., Chin. Chem. Lett. 32 (2021) 1341-1347. doi: 10.1016/j.cclet.2020.11.006
7. [7]
  H. He, Y. Lu, J. Qi, et al., Acta Pharm. Sin. B 9 (2019) 36-48. doi: 10.1016/j.apsb.2018.06.005
8. [8]
  K.T. Magar, G.F. Boafo, X. Li, Z. Chen, W. He, Chin. Chem. Lett. 33 (2022) 587–596. doi: 10.1016/j.cclet.2021.08.020
9. [9]
  Z. Shi, Q. Li, L. Mei, Chin. Chem. Lett. 31 (2020) 1345-1356. doi: 10.1016/j.cclet.2020.03.001
10. [10]
  X. Wang, I.S. Mohammad, L. Fan, et al., Acta Pharm. Sin. B 11 (2021) 2585-2604. doi: 10.1016/j.apsb.2021.04.010
11. [11]
  J. Di, F. Xie, Y. Xu, Adv. Drug Deliv. Rev. 154- 155 (2020) 151-162. doi: 10.1016/j.addr.2020.09.003
12. [12]
  S. Wang, Z. Zhong, J. Wan, et al., Am. J. Chin. Med. 41 (2013) 177-196. doi: 10.1142/S0192415X13500134
13. [13]
  S. Cao, Y. Huang, Q. Zhang, et al., Apoptosis 24 (2019) 33-45. doi: 10.1007/s10495-018-1497-0
14. [14]
  S. Chen, J. Gao, H.D. Halicka, et al., Int. J. Oncol. 26 (2005) 579-588.
15. [15]
  T. Fujita, Y. Takeda, S. Han-dong, et al., Planta Med. 54 (1988) 414-417. doi: 10.1055/s-2006-962485
16. [16]
  T. Ikezoe, S.S. Chen, X.J. Tong, et al., Int. J. Oncol. 23 (2003) 1187-1193.
17. [17]
  S. Xia, X. Zhang, C. Li, H. Guan, Saudi Pharm. J. 25 (2017) 638-643. doi: 10.1016/j.jsps.2017.04.037
18. [18]
  Z. Luo, Y. Dai, H. Gao, Acta Pharm. Sin. B 9 (2019) 1099-1112. doi: 10.1016/j.apsb.2019.06.004
19. [19]
  M. Zhang, S. Gao, D. Yang, et al., Acta Pharm. Sin. B 11 (2021) 2265-2285. doi: 10.1016/j.apsb.2021.03.033
20. [20]
  D. Luo, Y. Yi, K. Peng, et al., Eur. J. Med. Chem. 178 (2019) 365-379. doi: 10.1016/j.ejmech.2019.06.006
21. [21]
  F. Szoka, D. Papahadjopoulos, Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 4194-4198. doi: 10.1073/pnas.75.9.4194
22. [22]
  R.M. Clegg, Curr. Opin. Biotechnol. 6 (1995) 103-110. doi: 10.1016/0958-1669(95)80016-6
23. [23]
  E.A. Jares-Erijman, T.M. Jovin, Nat. Biotechnol. 21 (2003) 1387-1395. doi: 10.1038/nbt896
24. [24]
  W. Liu, D. Li, Z. Dong, et al., Int. J. Pharm. 587 (2020) 119682. doi: 10.1016/j.ijpharm.2020.119682
25. [25]
  D. Naor, S. Nedvetzki, I. Golan, L. Melnik, Y. Faitelson, Crit. Rev. Clin. Lab. Sci. 39 (2002) 527-579. doi: 10.1080/10408360290795574
26. [26]
  A. Cadete, M.J. Alonso, Nanomedicine 11 (2016) 2341-2357. doi: 10.2217/nnm-2016-0117
27. [27]
  E. Karousou, S. Misra, S. Ghatak, et al., Matrix Biol. 59 (2017) 3-22. doi: 10.1016/j.matbio.2016.10.001
28. [28]
  A. Spadea, J.M. Rios de la Rosa, A. Tirella, et al., Mol. Pharm. 16 (2019) 2481-2493. doi: 10.1021/acs.molpharmaceut.9b00083
29. [29]
  H. Zhang, J. Wang, W. Mao, et al., J. Control. Release 166 (2013) 147-158. doi: 10.1016/j.jconrel.2012.12.019
30. [30]
  N. O'Donovan, J. Crown, H. Stunell, et al., Clin. Cancer Res. 9 (2003) 738-742. doi: 10.1093/carcin/24.2.343
31. [31]
  D.C. Altieri, Oncogene 22 (2003) 8581-8589. doi: 10.1038/sj.onc.1207113
32. [32]
  X. Liu, S. Jiang, X. Tian, Y. Jiang, Int. J. Clin. Exp. Pathol. 11 (2018) 4363.
33. [33]
  T. Vántus, D. Vertommen, X. Saelens, et al., Cell. Signal. 16 (2004) 703-709. doi: 10.1016/j.cellsig.2003.11.009
34. [34]
  C. Teng, C. Lin, F. Huang, et al., Acta Pharm. Sin. B 10 (2020) 1521-1533. doi: 10.1016/j.apsb.2020.06.005
35. [35]
  X. Du, Y. Hou, J. Huang, et al., Acta Pharm. Sin. B 11 (2021) 3272-3285. doi: 10.1016/j.apsb.2021.03.014
36. [36]
  A.C. Krauss, X. Gao, L. Li, et al., Clin. Cancer Res. 25 (2019) 2685-2690. doi: 10.1158/1078-0432.ccr-18-2990
37. [37]
  Y.F. Wang, Q.S. Wu, J.D. Wang, et al., J. Control. Release 320 (2020) 457-468. doi: 10.1016/j.jconrel.2020.01.024
38. [38]
  W. Yu, M. Shevtsov, X. Chen, H. Gao, Chin. Chem. Lett. 31 (2020) 1366-1374. doi: 10.1016/j.cclet.2020.02.036
39. [39]
  S. Martin, H. Wang, T. Rathke, et al., Polymer 102 (2016) 342-349. doi: 10.1016/j.polymer.2016.02.019
40. [40]
  M. Milinkovic, J.H. Antin, C.A. Hergrueter, C.B. Underhill, R. Sackstein, Blood 103 (2004) 740–742. doi: 10.1182/blood-2003-05-1500
41. [41]
  K. Greish, G. Thiagarajan, H. Herd, et al., Nanotoxicology 6 (2012) 713-723. doi: 10.3109/17435390.2011.604442
42. [42]
  L.F. Zhang, S. Granick, Nano Lett. 6 (2006) 694-698. doi: 10.1021/nl052455y
43. [43]
  G.T. Qin, Z. Li, R.M. Xia, et al., Nanotechnology 22 (2011) 155605. doi: 10.1088/0957-4484/22/15/155605
44. [44]
  Z.J. Chen, S.C. Yang, X.L. Liu, et al., Nano Lett. 20 (2020) 4177-4187. doi: 10.1021/acs.nanolett.0c00495
45. [45]
  Y. Lv, C. Xu, X. Zhao, et al., ACS Nano 12 (2018) 1519-1536. doi: 10.1021/acsnano.7b08051
46. [46]
  E. Devarajan, A.A. Sahin, J.S. Chen, et al., Oncogene 21 (2002) 8843-8851. doi: 10.1038/sj.onc.1206044
47. [47]
  R.N. Winter, A. Kramer, A. Borkowski, N. Kyprianou, Cancer Res. 61 (2001) 1227. doi: 10.1097/00002820-200102000-00011
1. [1]
  Yunjie Dang , Yanru Feng , Xiao Chen , Chaoxing He , Shujie Wei , Dingyang Liu , Jinlong Qi , Huaxing Zhang , Shaokun Yang , Zhiyun Niu , Bai Xiang . Development of a multi-level pH-responsive lipid nanoplatform for efficient co-delivery of siRNA and small-molecule drugs in tumor treatment. Chinese Chemical Letters, 2024, 35(12): 109660-. doi: 10.1016/j.cclet.2024.109660
2. [2]
  Cheng-Zhe Gao , Hao-Ran Jia , Tian-Yu Wang , Xiao-Yu Zhu , Xiaofeng Han , Fu-Gen Wu . A dual drug-loaded tumor vasculature-targeting liposome for tumor vasculature disruption and hypoxia-enhanced chemotherapy. Chinese Chemical Letters, 2025, 36(1): 109840-. doi: 10.1016/j.cclet.2024.109840
3. [3]
  Wenbin Zhou , Yafei Gao , Xinyu Feng , Yanqing Zhang , Cong Yang , Lanxi He , Fenghe Zhang , Xiaoguang Li , Qing Li . Biomimetic nanoplatform integrates FRET-enhanced photodynamic therapy and chemotherapy for cascaded revitalization of the tumor immune microenvironment in OSCC. Chinese Chemical Letters, 2025, 36(1): 109763-. doi: 10.1016/j.cclet.2024.109763
4. [4]
  Ying Gao , Rong Zhou , Qiwen Wang , Shaolong Qi , Yuanyuan Lv , Shuang Liu , Jie Shen , Guocan Yu . Natural killer cell membrane doped supramolecular nanoplatform with immuno-modulatory functions for immuno-enhanced tumor phototherapy. Chinese Chemical Letters, 2024, 35(10): 109521-. doi: 10.1016/j.cclet.2024.109521
5. [5]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562
6. [6]
  Chuyu Huang , Zhishan Liu , Linping Zhao , Zuxiao Chen , Rongrong Zheng , Xiaona Rao , Yuxuan Wei , Xin Chen , Shiying Li . Metal-coordinated oxidative stress amplifier to suppress tumor growth combined with M2 macrophage elimination. Chinese Chemical Letters, 2024, 35(12): 109696-. doi: 10.1016/j.cclet.2024.109696
7. [7]
  Zhi Li , Shuya Pan , Yuan Tian , Shaowei Liu , Weifeng Wei , Jinlin Wang , Tianfeng Chen , Ling Wang . Selenium nanoparticles enhance the chemotherapeutic efficacy of pemetrexed against non-small cell lung cancer. Chinese Chemical Letters, 2024, 35(12): 110018-. doi: 10.1016/j.cclet.2024.110018
8. [8]
  Du Liu , Yuyan Li , Hankun Zhang , Benhua Wang , Chaoyi Yao , Minhuan Lan , Zhanhong Yang , Xiangzhi Song . Three-in-one erlotinib-modified NIR photosensitizer for fluorescence imaging and synergistic chemo-photodynamic therapy. Chinese Chemical Letters, 2025, 36(2): 109910-. doi: 10.1016/j.cclet.2024.109910
9. [9]
  Peide Zhu , Yangjia Liu , Yaoyao Tang , Siqi Zhu , Xinyang Liu , Lei Yin , Quan Liu , Zhiqiang Yu , Quan Xu , Dixian Luo , Juncheng Wang . Bi-doped carbon quantum dots functionalized liposomes with fluorescence visualization imaging for tumor diagnosis and treatment. Chinese Chemical Letters, 2024, 35(4): 108689-. doi: 10.1016/j.cclet.2023.108689
10. [10]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
11. [11]
  Weijian Zhang , Xianyu Deng , Liying Wang , Jian Wang , Xiuting Guo , Lianggui Huang , Xinyi Wang , Jun Wu , Linjia Jiang . Poly(ferulic acid) nanocarrier enhances chemotherapy sensitivity of acute myeloid leukemia by selectively targeting inflammatory macrophages. Chinese Chemical Letters, 2024, 35(9): 109422-. doi: 10.1016/j.cclet.2023.109422
12. [12]
  Yanfei Liu , Yaqin Hu , Yifu Tan , Qiwen Chen , Zhenbao Liu . Tumor acidic microenvironment activatable DNA nanostructure for precise cancer cell targeting and inhibition. Chinese Chemical Letters, 2025, 36(1): 110289-. doi: 10.1016/j.cclet.2024.110289
13. [13]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
14. [14]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
15. [15]
  Wen Xiao , Fazhan Wang , Yangzhuo Gu , Xi He , Na Fan , Qian Zheng , Shugang Qin , Zhongshan He , Yuquan Wei , Xiangrong Song . PEG400-mediated nanocarriers improve the delivery and therapeutic efficiency of mRNA tumor vaccines. Chinese Chemical Letters, 2024, 35(5): 108755-. doi: 10.1016/j.cclet.2023.108755
16. [16]
  Xiangqian Cao , Chenkai Yang , Xiaodong Zhu , Mengxin Zhao , Yilin Yan , Zhengnan Huang , Jinming Cai , Jingming Zhuang , Shengzhou Li , Wei Li , Bing Shen . Synergistic enhancement of chemotherapy for bladder cancer by photothermal dual-sensitive nanosystem with gold nanoparticles and PNIPAM. Chinese Chemical Letters, 2024, 35(8): 109199-. doi: 10.1016/j.cclet.2023.109199
17. [17]
  Jinyu Guo , Yandai Lin , Shaohua He , Yueqing Chen , Fenglu Li , Renjie Ruan , Gaoxing Pan , Hexin Nan , Jibin Song , Jin Zhang . Utilizing dual-responsive iridium(Ⅲ) complex for hepatocellular carcinoma: Integrating photoacoustic imaging with chemotherapy and photodynamic therapy. Chinese Chemical Letters, 2024, 35(9): 109537-. doi: 10.1016/j.cclet.2024.109537
18. [18]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
19. [19]
  Han Han , Bi-Te Chen , Jia-Rong Ding , Jin-Ming Si , Tian-Jiao Zhou , Yi Wang , Lei Xing , Hu-Lin Jiang . A PDGFRβ-targeting nanodrill system for pancreatic fibrosis therapy. Chinese Chemical Letters, 2024, 35(10): 109583-. doi: 10.1016/j.cclet.2024.109583
20. [20]
  Shaoqing Du , Xinyong Liu , Xueping Hu , Peng Zhan . Targeting novel sites represents an effective strategy for combating drug resistance. Chinese Chemical Letters, 2025, 36(1): 110378-. doi: 10.1016/j.cclet.2024.110378

Get Citation

PDF

XML

Metrics

PDF Downloads(2)
Abstract views(651)
HTML views(55)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142